1. Home
  2. MLYS vs VCEL Comparison

MLYS vs VCEL Comparison

Compare MLYS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$29.93

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$46.70

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
VCEL
Founded
2019
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
MLYS
VCEL
Price
$29.93
$46.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$48.67
$57.75
AVG Volume (30 Days)
1.8M
712.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
60.00
EPS
N/A
N/A
Revenue
N/A
$276,259,000.00
Revenue This Year
N/A
$19.40
Revenue Next Year
N/A
$18.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.45
52 Week Low
$12.59
$28.95
52 Week High
$47.65
$47.79

Technical Indicators

Market Signals
Indicator
MLYS
VCEL
Relative Strength Index (RSI) 66.82 73.94
Support Level $25.88 $32.47
Resistance Level $31.29 N/A
Average True Range (ATR) 1.42 1.75
MACD 0.65 0.40
Stochastic Oscillator 84.16 88.72

Price Performance

Historical Comparison
MLYS
VCEL

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: